<DOC>
	<DOC>NCT02305797</DOC>
	<brief_summary>To evaluate the efficacy of EDG004 compared to placebo for the treatment of adult patients with GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 5th Ed. (DSM-5) and confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0). Efficacy will be measured by a statistically significant greater mean reduction from baseline compared to endpoint in anxiety symptoms as measured by the total score of the clinician-rated Hamilton Rating Scale for Anxiety (HAM-A) for the EDG004 treatment group compared to placebo.</brief_summary>
	<brief_title>EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Men and women between the ages of 1865 years and Diagnosed with GAD and No other psychiatric conditions, and are otherwise medically healthy. Women who are pregnant or lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>